Analysis of proteomic data reveals potential therapeutic targets for cancer
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
List view / Grid view
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
Researchers have used artificial intelligence to screen 80 FDA-approved drugs and reveal which could be used as Alzheimer's treatments.
A novel in silico approach applied to drug screening has revealed three potential candidates that may interact with multiple proteins of SARS‐CoV‐2.
A new coarse-grained model of the complete SARS-CoV-2 virion has revealed potential new ways to combat the coronavirus.
A team has demonstrated that their bioinformatics approach, PlasmidHawk, can analyse DNA sequences to identify the source of engineered plasmids.
Researchers have developed a new technique called mim-tRNAseq to measure, map and analyse tRNAs in cells, providing insight into disease.
Researchers have used computer simulations to model how the SARS-CoV-2 fusion peptide interacts with and penetrates the cell membrane.
With the right solution organisations can simplify their lab-based working, while ensuring the highest level of compliance with regulatory requirements.
Researchers have developed a computer modelling programme that can produce genetic circuits for cellular engineering.
A team has developed a machine learning approach to screen for and identify drugs that could be repurposed against COVID-19 in the elderly.
A study has used artificial intelligence to reveal adeno-associated virus (AAV) capsid variants for use in gene therapies.
In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
Researchers have developed a personalised medicine platform that could advance genomic medicine research for cancer.
Researchers have developed a new mass spectrometer that uses rotation frequencies of ionised molecules to measure mass with high accuracy.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.